Sasamoto Koki, Yanagida Noriyuki, Nagakura Ken-Ichi, Nishino Makoto, Sato Sakura, Ebisawa Motohiro
Department of Pediatrics, National Hospital Organization, Sagamihara National Hospital, Kanagawa, Japan.
Department of Pediatrics, Toho University Ohashi Medical Center, Tokyo, Japan.
J Allergy Clin Immunol Glob. 2022 Apr 30;1(3):138-144. doi: 10.1016/j.jacig.2022.03.005. eCollection 2022 Aug.
Studies of long-term oral immunotherapy (OIT) in children with anaphylactic egg allergy are limited.
Our aim was to investigate the long-term outcomes of OIT for anaphylactic egg allergy.
The participants included children (aged ≥ 5 years) with a history of anaphylaxis in response to eggs and objective reactions to oral food challenge (OFC) with 250 mg of egg protein. In the OIT group, the home starting dose of egg protein set during 5 days of hospitalization was ingested once daily and gradually increased to 1000 mg. Over the next year, participants temporarily discontinued OIT for 2 weeks and underwent OFC with 3100 mg of egg protein annually until they passed. The historical control group comprised patients who did not receive OIT and repeated OFCs annually.
In the OIT group (n = 20), the baseline median egg white- and ovomucoid-specific IgE levels were 45.5 and 38.5 kU/L, respectively. The rate of passing OFC with 3100 mg of egg protein gradually increased in the OIT group, with rates of 20% at 1 year, 35% at 2 years, and 55% at 3 years, which were significantly higher than the rates in the historical control group at 3 years (5% [ < .001]). In the OIT group, 5 anaphylaxis events (0.04%) occurred at home, and 1 participant required intramuscular adrenaline. Furthermore, egg white- and ovomucoid-specific IgE levels decreased significantly after 3 years in both groups, whereas in the OIT group, these specific IgG and IgG levels increased significantly after a year.
Long-term OIT accelerated immunologic changes and enabled ingestion of 3100 mg of egg protein in half of the participants with anaphylactic egg allergy.
关于对过敏性鸡蛋过敏儿童进行长期口服免疫疗法(OIT)的研究有限。
我们的目的是研究OIT治疗过敏性鸡蛋过敏的长期效果。
参与者包括有鸡蛋过敏反应史且对250毫克鸡蛋蛋白进行口服食物激发试验(OFC)有客观反应的儿童(年龄≥5岁)。在OIT组中,住院5天期间设定的家庭起始鸡蛋蛋白剂量每日服用一次,并逐渐增加至1000毫克。在接下来的一年中,参与者暂时停止OIT 2周,并每年接受3100毫克鸡蛋蛋白的OFC,直至通过。历史对照组包括未接受OIT且每年重复进行OFC的患者。
在OIT组(n = 20)中,基线时蛋清和类卵黏蛋白特异性IgE水平分别为45.5和38.5 kU/L。OIT组中通过3100毫克鸡蛋蛋白OFC的比例逐渐增加,1年时为20%,2年时为35%,3年时为55%,显著高于历史对照组3年时的比例(5%[<0.001])。在OIT组中,5例过敏反应事件(0.